Emyria (ASX:EMD)

Broker Briefing Webinar | Michael Winlo, CEO

only

Emyria develops biopharmaceuticals

guided by Real-WorldData collected

usenal

with patients receiving care at our

clinics

1

Emyria is a biotech that, uniquely:

provides care, generates data & develops treatments

only

Care

Patients w

unmet needs +

new

treatments

5 clinical sites (Emerald Clinics) treating

more than 40 complex conditions in

use

>6,000 patients aged 2-98.

2

nal

Care
Patients w
unmet needs +
new
treatments

Emyria is a biotech that, uniquely:

provides care, generates data & develops treatments

nal use only

5 clinical sites (Emerald Clinics) treating more than 40 complex conditions in >6,000 patients aged 2-98.

Data

Insights from

Real-World

Data (RWD)

One of the largest patient registries of ethically sourced Real-World Data (RWD) on treatment effects of GMP-gradecannabinoids to guide biopharmaceutical development.

3

Care
Patients w
unmet needs +
new
treatments

Emyria is a biotech that, uniquely:

provides care, generates data & develops treatments

nal use only

5 clinical sites (Emerald Clinics) treating more than 40 complex conditions in >6,000 patients aged 2-98.

Data

Insights from

Real-World

Data (RWD)

One of the largest patient registries of ethically sourced Real-World Data (RWD) on treatment effects of GMP-gradecannabinoids to guide biopharmaceutical development.

Treatments

Proprietary

drug design +

global

registration

2 FDA-compliant drug development

programs seeking registration with major global regulators. More in development.

4

Emyria's active clinical development programs

Platform

Active programs

Initial opportunities

onlyuse

Ultra-pure

Low-doseCBD for

Over-the-counter treatment

cannabinoid-

EMD

-RX5

for psychological distress

based medical

multiple indications

$200m/yr (Australia alone)

treatments

(CBMTs)

See ASX Announcement 19 October 2021

High-doseCBD for

EMD

-RX7

multiple indications

nal

[1] https://www.coherentmarketinsights.com/market-insight/post-traumatic-stress-disorder-treatment-market-4433

Next 3-6 months

  • Complete pivotal trials
  • TGA registration application
  • New formulations
  • Launch US registration programs

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Emyria Ltd. published this content on 24 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 March 2022 04:17:03 UTC.